EUVIMEDEUVIMED entdecken
Open Access

Human stem cell-derived β cells expressing an optimized CD155 reduce cytotoxic immune cell function for application in type 1 diabetes

Matthew E Brown iD, Jessie M Barra iD, Marcus R Pina iD, James Proia iD, Todd M Brusko iD, Holger A Russ iD

Science Advances · 2025

DOI: 10.1126/sciadv.adx9755 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Advances, 2025. Verfasst von Matthew E Brown und 5 weiteren Autor:innen. Beteiligte Einrichtung: Diabetes Institute, University of Florida, Gainesville, FL, USA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Insulin-Secreting Cells, Receptors, Virus, Cytotoxicity, Immunologic. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NIDDK NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Insulin-producing β cell replacement therapies show promise for treating type 1 diabetes (T1D), but challenges such as donor shortages and immune rejection persist. Stem cell–derived β cells (sBC) provide a renewable source but remain susceptible to immune attack. We engineered human pluripotent stem cells to express either the wild type (WT) or a high-affinity mutant (Mut) variant (rs1058402, G>A; Ala 67 Thr) of the natural killer (NK) and T cell checkpoint inhibitor CD155 before differentiation into sBC. Modified sBC maintained up-regulated CD155 expression and showed enhanced binding to co-receptor ligands. Co-culture studies revealed CD155-expressing sBC suppressed autoreactive CD8 + T cell and NK cell activation, reducing immune cell–mediated sBC destruction and cytotoxic molecule secretion by preferentially engaging the coinhibitory receptor TIGIT. This protection was lost with TIGIT blockade, affirming the role of CD155-TIGIT signaling in antagonizing immune cell cytotoxicity. Our findings suggest that high-affinity CD155 expression enhances immune evasion of sBC, improving their potential as a therapy for T1D.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 1Insulin-Secreting CellsReceptors, VirusCytotoxicity, ImmunologicHumansKiller Cells, NaturalReceptors, ImmunologicCell DifferentiationCD8-Positive T-Lymphocytes

Substanzen

poliovirus receptorReceptors, VirusReceptors, ImmunologicTIGIT protein, human

Autor:innen und Institutionen

  • Diabetes Institute, University of Florida, Gainesville, FL, USA.
  • Department of Pathology, Immunology and Laboratory Medicine, College of Medicine, University of Florida, Gainesville, FL, USA.
  • Department of Pharmacology and Therapeutics, College of Medicine, University of Florida, Gainesville, FL, USA.
  • Department of Pediatrics, College of Medicine, University of Florida, Gainesville, FL, USA.
  • Department of Biochemistry and Molecular Biology, College of Medicine, University of Florida, Gainesville, FL, USA.

ORCID-Profile: Matthew E Brown, Jessie M Barra, Marcus R Pina, James Proia, Todd M Brusko, Holger A Russ

Förderung

  • NIAID NIH HHS
  • NIDDK NIH HHS

Zitieren

APA

Brown, M. E., Barra, J. M., Pina, M. R., Proia, J., Brusko, T. M., & Russ, H. A. (2025). Human stem cell-derived β cells expressing an optimized CD155 reduce cytotoxic immune cell function for application in type 1 diabetes. Science Advances. https://doi.org/10.1126/sciadv.adx9755

Vancouver

Brown ME, Barra JM, Pina MR, Proia J, Brusko TM, Russ HA. Human stem cell-derived β cells expressing an optimized CD155 reduce cytotoxic immune cell function for application in type 1 diabetes. Science Advances. 2025. doi:10.1126/sciadv.adx9755

BibTeX
@article{Brown2025,
  author = {Brown, Matthew E and Barra, Jessie M and Pina, Marcus R and Proia, James and Brusko, Todd M and Russ, Holger A},
  title = {Human stem cell-derived β cells expressing an optimized CD155 reduce cytotoxic immune cell function for application in type 1 diabetes},
  journal = {Science Advances},
  year = {2025},
  doi = {10.1126/sciadv.adx9755}
}
Kostenlos starten →